We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Novel Class of Drug Delivery Liposomes Fail to Trigger an Adverse Immune Response

By LabMedica International staff writers
Posted on 22 Mar 2016
Print article
Image: Drug molecules (red) are embedded in a water-filled cavity inside of the phospholipid vesicle (Photo courtesy of the University of Basel/University of Fribourg).
Image: Drug molecules (red) are embedded in a water-filled cavity inside of the phospholipid vesicle (Photo courtesy of the University of Basel/University of Fribourg).
A novel class of liposomes prepared from the artificial phospholipid Pad-PC-Pad releases drugs at the site of arterial blockage, and has been shown to avoid activation of deleterious immune responses.

One therapeutic approach for treatment of atherosclerosis is a liposome-based drug carrier system specifically targeting constricted arteries. Vesicles made from an artificial 1,3-diaminophospholipid are stable under static conditions but release their contents at elevated shear stress. These vesicles have a lenticular morphology, which potentially leads to instabilities along their equator. A model cardiovascular system based on polymer tubes and an external pump to represent shear stress in healthy and constricted vessels of the heart showed that drugs preferentially released from the vesicles in constricted vessels that had high shear stress.

While these liposomes are promising delivery containers, they are recognized as foreign by the immune system. Complement activation, an essential factor of the recognition, leads to adverse effects on the organism.

Investigators at the University of Basel (Switzerland) and the University of Fribourg (Switzerland) tested complement activation by liposomes formulated from the artificial phospholipid Pad-PC-Pad in vitro. They reported in the December 27, 2015, online edition of the journal Nanomedicine: Nanotechnology, Biology, and Medicine that no complement activation was detected in human sera and porcine plasma. In in-vivo experiments with three pigs, neither anaphylactic reactions nor other significant hemodynamic changes were observed even at comparably high liposome doses.

"The study shows that Pad-PC-Pad liposomes are not inducing direct or indirect anaphylactic reactions, even at high dosages", said senior author Dr. Bert Müller, professor of materials science in medicine at the University of Basel. "These are highly unexpected results could have a high impact of future treatments of atherosclerosis."

Related Links:

University of Basel
University of Fribourg


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.